Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Passes Above 200-Day Moving Average – What’s Next?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.83 and traded as high as $3.07. Sonoma Pharmaceuticals shares last traded at $2.98, with a volume of 23,564 shares changing hands.

Sonoma Pharmaceuticals Stock Performance

The company has a market cap of $4.89 million, a P/E ratio of -0.96 and a beta of 1.33. The business has a 50 day moving average price of $3.20 and a two-hundred day moving average price of $2.83.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Tuesday, June 17th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.58. Sonoma Pharmaceuticals had a negative return on equity of 58.73% and a negative net margin of 24.23%. The business had revenue of $3.75 million for the quarter, compared to analysts’ expectations of $4.44 million. As a group, research analysts expect that Sonoma Pharmaceuticals, Inc. will post -0.67 EPS for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.